Literature DB >> 10719727

Cell cycle proteins do not predict outcome in grade I infiltrating ductal carcinoma of the breast.

A C Leong1, A M Hanby, H W Potts, D S Tan, D Skilton, K Ryder, W H Harris, R D Liebmann, D M Barnes, C E Gillett.   

Abstract

Infiltrating ductal mammary carcinomas are histologically graded according to their extent of differentiation. Well-differentiated, grade I, tumours have low proliferative activity, usually form tubules and exhibit little nuclear pleomorphism. Despite an apparently reassuring morphology, 10-15% of grade I ductal carcinomas metastasize, albeit after a prolonged period. Recent evidence supports the view that evolution to higher grade malignancies occurs rarely and that grade I tumours are biologically distinct from grade III tumours. We have examined a series of 148 grade I ductal carcinomas in order to ascertain whether information about the level of expression of cyclin D1, p27, p53, oestrogen receptor status (ER) or proliferative activity could be used to identify those patients with a poor outcome. The majority of tumours expressed high levels of cyclin D1, p27 and ER, low levels of p53 and had low Ki-67 expression and mitotic counts. Cyclin D1, p27 and ER expression were all significantly correlated with each other but not with p53 (cyclin D1 correlation with ER, p = 0.01; cyclin D1 correlation with p27 and ER correlation with p27 both p < 0.0001). Cyclin D1 and ER were also both correlated with Ki-67 (p = 0.01 and p < 0.0001) but not with mitotic count. Our results suggest that cyclin D1, ER and p27 are all markers of well-differentiated tumours and that their detection is related to proliferative activity in a manner reflecting their functional role within the normal cell cycle. However, none of the proteins or markers of proliferative activity were sensitive enough to predict which patients were likely to have a poor outcome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10719727     DOI: 10.1002/(sici)1097-0215(20000120)89:1<26::aid-ijc5>3.0.co;2-8

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

Review 1.  p27 deregulation in breast cancer: prognostic significance and implications for therapy.

Authors:  A Alkarain; R Jordan; J Slingerland
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

2.  Cytoplasmic expression of p27(kip1) is associated with a favourable prognosis in colorectal cancer patients.

Authors:  Nicholas F S Watson; Lindy G Durrant; John H Scholefield; Zahra Madjd; Duncan Scrimgeour; Ian Spendlove; Ian O Ellis; Poulam M Patel
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

Review 3.  The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer.

Authors:  R Chiarle; M Pagano; G Inghirami
Journal:  Breast Cancer Res       Date:  2000-12-20       Impact factor: 6.466

4.  Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment.

Authors:  R Michalides; H van Tinteren; A Balkenende; J B Vermorken; J Benraadt; J Huldij; P van Diest
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

5.  Immunodetectable cyclin D(1)is associated with oestrogen receptor but not Ki67 in normal, cancerous and precancerous breast lesions.

Authors:  B S Shoker; C Jarvis; M P Davies; M Iqbal; D R Sibson; J P Sloane
Journal:  Br J Cancer       Date:  2001-04-20       Impact factor: 7.640

Review 6.  Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer.

Authors:  Angel Alkarain; Joyce Slingerland
Journal:  Breast Cancer Res       Date:  2003-10-21       Impact factor: 6.466

Review 7.  p27(Kip1) as a prognostic factor in breast cancer: a systematic review and meta-analysis.

Authors:  Xiaoxiang Guan; Yucai Wang; Ruilian Xie; Longbang Chen; Jianling Bai; Jia Lu; Macus Tien Kuo
Journal:  J Cell Mol Med       Date:  2010-02-27       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.